ROR family includes receptor tyrosine kinases ROR1 and ROR2.
ROR1 is of particular interest to the pharmaceutical community, because its expression is only observed in embryonic and cancerous cells, but not in health adult tissues.
This feature makes it an ideal drug target for several cancer types.
Multiple ROR1-targeted therapies are underdevelopment, including Oncternal’s Cirmtuzumab.
The extracellular domain of ROR1 is made of three distinct domains, an immunoglobulin-like (Ig) domain, a frizzled domain, and a kringle domain (Borcherding et al., 2014).
Interestingly, antibodies targeting different domains demonstrate a marked difference in therapeutic efficacy when used to treat leukemia cell lines (Daneshmanesh et al., 2013).
05 ROR Proteins_Flyer_20161230.pdf